Boston Sci Ponies Up $1.6B for Urology Tech

Boston Scientific Corp. has reentered the medtech mergers and acquisitions fray with a major urology tech acquisition.

Chris Newmarker

Boston Scientific announced this week that it has agreed to acquire Endo International's American Medical Systems urology portfolio for $1.6 billion.

In 2014, the Endo business unit had sales of approximately $400 million.

The deal includes the AMS product portfolio for treating urologic conditions, including benign prostatic hyperplasia (BPH), male stress urinary incontinence, and erectile dysfunction.

From Boston Scientific executives' point of view, the technologies complement the Marlborough, MA-based device companies' kidney stone, pelvic organ prolapse, female stress urinary incontinence, and abnormal uterine bleeding treatment portfolios.

"The combination of Boston Scientific's Urology and Women's Health and AMS' urology portfolios will create a business with nearly $1 billion in annual sales and enable significant synergies and strong future growth prospects through portfolio innovation and international market expansion," Boston Scientific president and CEO Mike Mahoney said in a news release.

In recent years, Boston Scientific has steadily diversifying its business, which has been largely reliant historically on cardiac devices, which still amount to half of the company's sales.

For its part, Endo will sharpen its focus on pharmaceuticals following the sale of the urology technology unit.

Chris Newmarker is senior editor of Qmed and MPMN. Follow him on Twitter at @newmarker.

Like what you're reading? Subscribe to our daily e-newsletter.